Syno Capital

Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for serious diseases that currently lack approved therapies. Established in 2016 and based in New York, the company is advancing a pipeline of novel product candidates that target high unmet medical needs, including cardiovascular diseases and metabolic disorders. Its lead candidate, AT-007, is in Phase I/II trials aimed at treating galactosemia. Additionally, AT-001 is undergoing Phase II trials for diabetic cardiomyopathy and Phase I trials for diabetic peripheral neuropathy, while AT-003 is in Phase I trials for diabetic retinopathy. The company also has preclinical candidates such as AT-104, intended for orphan hematological oncology conditions, demonstrating its commitment to addressing critical health challenges through targeted therapeutics.

PhaseBio Pharmaceuticals, Inc., established in 2002 and based in Malvern, Pennsylvania, is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for cardiopulmonary diseases. Its primary focus is on PB2452, a reversal agent for the antiplatelet drug ticagrelor, currently in Phase III trials for managing uncontrolled bleeding events or urgent surgeries. Additionally, PhaseBio is developing PB1046, a fusion protein in Phase IIb trials for treating pulmonary arterial hypertension, and PB6440, an oral agent for resistant hypertension. The company's proprietary technology, elastin-like polypeptides (ELPs), enhances the stability, bioavailability, and efficacy of proteins and peptides, aiming to improve patient outcomes and reduce side effects.

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company based in Cambridge, Massachusetts, focuses on developing novel T cell receptor therapies for cancer treatment. Founded in 2015 by Dr. Patrick Baeuerle and MPM Capital, TCR2 specializes in engineering T cells to target specific antigens expressed by cancer cells. The company's lead product candidates include TC-210, which targets mesothelin-positive solid tumors such as non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma; and TC-110, targeting CD19-positive B-cell hematological malignancies. TCR2's pipeline also includes candidates for adult acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and follicular lymphoma. The company's approach is distinct from traditional CAR-T cells and other engineered T cell therapies, leveraging a deep understanding of T cell receptor biology to create highly differentiated treatments.

ORIG3N, Inc. is a biotechnology company focused on developing innovative treatments for rare genetically inherited diseases, particularly targeting conditions related to the heart, liver, and neurodegeneration. Founded in 2014 and based in Boston, Massachusetts, ORIG3N utilizes induced pluripotent stem cell technology that allows for the differentiation of cells into any type found in the body. This technology is employed to test drug efficacy, screen for medication toxicity, and create personalized treatment pathways. The company offers a range of products, including LifeProfiles, which provides genetic insights related to fitness, metabolism, and exercise recovery; the Run DNA test for optimizing running performance; AURA, which assesses skin health; and Life Capsule, a repository for blood cells aimed at regenerative medicine development.

Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for serious diseases that currently lack approved therapies. Established in 2016 and based in New York, the company is advancing a pipeline of novel product candidates that target high unmet medical needs, including cardiovascular diseases and metabolic disorders. Its lead candidate, AT-007, is in Phase I/II trials aimed at treating galactosemia. Additionally, AT-001 is undergoing Phase II trials for diabetic cardiomyopathy and Phase I trials for diabetic peripheral neuropathy, while AT-003 is in Phase I trials for diabetic retinopathy. The company also has preclinical candidates such as AT-104, intended for orphan hematological oncology conditions, demonstrating its commitment to addressing critical health challenges through targeted therapeutics.

Honor is a leading senior care network and technology platform that focuses on enhancing the quality of life for older adults and their families. Founded in 2014 by Cameron Ring, Monica Lo, Sandy Jen, and Seth Sternberg in San Francisco, California, Honor has established itself as a pioneer in the home care industry. The company offers expert in-home care services for seniors, leveraging an integrated system of third-party care providers. By combining scalable workforce management with personalized care, Honor enables older adults to live safely and comfortably in their own homes. In 2021, Honor expanded its reach by acquiring Home Instead, enhancing its capabilities through a global network and a relationship-based care model. This strategic move positions Honor to address the evolving needs of aging adults and professional caregivers worldwide.

ORIG3N, Inc. is a biotechnology company focused on developing innovative treatments for rare genetically inherited diseases, particularly targeting conditions related to the heart, liver, and neurodegeneration. Founded in 2014 and based in Boston, Massachusetts, ORIG3N utilizes induced pluripotent stem cell technology that allows for the differentiation of cells into any type found in the body. This technology is employed to test drug efficacy, screen for medication toxicity, and create personalized treatment pathways. The company offers a range of products, including LifeProfiles, which provides genetic insights related to fitness, metabolism, and exercise recovery; the Run DNA test for optimizing running performance; AURA, which assesses skin health; and Life Capsule, a repository for blood cells aimed at regenerative medicine development.

LungLife AI, Inc. is a clinical diagnostics company based in Thousand Oaks, California, specializing in the early detection and management of lung cancer through the molecular analysis of cancer biomarkers in blood. The company utilizes machine learning and artificial intelligence to enhance the accuracy and efficiency of cancer diagnosis and treatment. LungLife AI offers a range of products, including the LiquidBiopsy platform for isolating rare cells from blood samples and the Everest software for sequence analysis. Additionally, it provides CLIA/CAP lab services, such as the ClearID test for identifying targetable DNA mutations and the NK Vue test for monitoring immune system health. The company's offerings aim to improve treatment stratification and monitoring across all stages of lung cancer. LungLife AI was founded in 2006 and was formerly known as Cynvenio Biosystems, Inc. It also maintains a strategic collaboration with the Institute of Regional Health Research.